156 related articles for article (PubMed ID: 21337682)
21. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
[TBL] [Abstract][Full Text] [Related]
22. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
23. Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
Gupta S; Wang C; Raetz EA; Schore R; Salzer WL; Larsen EC; Maloney KW; Mattano LA; Carroll WL; Winick NJ; Hunger SP; Loh ML; Devidas M
J Clin Oncol; 2020 Jun; 38(17):1897-1905. PubMed ID: 32275469
[TBL] [Abstract][Full Text] [Related]
24. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
Boos J
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
[TBL] [Abstract][Full Text] [Related]
26. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
[TBL] [Abstract][Full Text] [Related]
27. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
[TBL] [Abstract][Full Text] [Related]
28. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
29. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J
Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
[TBL] [Abstract][Full Text] [Related]
30. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
[TBL] [Abstract][Full Text] [Related]
31. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
Mondelaers V; Ferster A; Uyttebroeck A; Brichard B; van der Werff Ten Bosch J; Norga K; Francotte N; Piette C; Vandemeulebroecke K; Verbeke C; Schmidt S; Benoit Y; Lammens T; De Moerloose B
Br J Haematol; 2020 Jul; 190(1):105-114. PubMed ID: 32057100
[TBL] [Abstract][Full Text] [Related]
32. Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961).
Grigoryan RS; Panosyan EH; Seibel NL; Gaynon PS; Avramis IA; Avramis VI
In Vivo; 2004; 18(2):107-12. PubMed ID: 15113036
[TBL] [Abstract][Full Text] [Related]
33. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
Dibenedetto SP; Di Cataldo A; Ragusa R; Meli C; Lo Nigro L
J Clin Oncol; 1995 Feb; 13(2):339-44. PubMed ID: 7844595
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase.
Asselin BL; Ryan D; Frantz CN; Bernal SD; Leavitt P; Sallan SE; Cohen HJ
Cancer Res; 1989 Aug; 49(15):4363-8. PubMed ID: 2743326
[TBL] [Abstract][Full Text] [Related]
35. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
[TBL] [Abstract][Full Text] [Related]
36. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Vrooman LM; Stevenson KE; Supko JG; O'Brien J; Dahlberg SE; Asselin BL; Athale UH; Clavell LA; Kelly KM; Kutok JL; Laverdière C; Lipshultz SE; Michon B; Schorin M; Relling MV; Cohen HJ; Neuberg DS; Sallan SE; Silverman LB
J Clin Oncol; 2013 Mar; 31(9):1202-10. PubMed ID: 23358966
[TBL] [Abstract][Full Text] [Related]
37. [Cells antigens' expression modulation during induction treatment of childhood acute lymphoblastic leukemia].
Pawińska-Wasikowska K; Balwierz W
Przegl Lek; 2010; 67(6):361-5. PubMed ID: 21344762
[TBL] [Abstract][Full Text] [Related]
38. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
Attarbaschi A; Mann G; Dworzak M; Urban C; Fink FM; Dieckmann K; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Feb; 114(4):148-57. PubMed ID: 12060981
[TBL] [Abstract][Full Text] [Related]
39. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
Cohen H; Bielorai B; Harats D; Toren A; Pinhas-Hamiel O
Pediatr Blood Cancer; 2010 May; 54(5):703-6. PubMed ID: 20063421
[TBL] [Abstract][Full Text] [Related]
40. Comparative pharmacokinetic studies of three asparaginase preparations.
Asselin BL; Whitin JC; Coppola DJ; Rupp IP; Sallan SE; Cohen HJ
J Clin Oncol; 1993 Sep; 11(9):1780-6. PubMed ID: 8355045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
